An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for
Pneumocystis pneumonia
drug discontinuation rate
efficacy
prophylaxis
randomized controlled trial
rheumatic disease
safety
sulfamethoxazole–trimethoprim
Journal
Rheumatology advances in practice
ISSN: 2514-1775
Titre abrégé: Rheumatol Adv Pract
Pays: England
ID NLM: 101736676
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
04
2020
revised:
10
06
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
The aim was to investigate the long-term prophylactic efficacy, drug retention and safety of low-dose sulfamethoxazole-trimethoprim (SMX/TMP) prophylaxis against Adult patients with rheumatic diseases receiving prednisolone ≥0.6 mg/kg/day were randomized into the single-strength group (SS; SMX/TMP 400/80 mg daily), the half-strength group (HS; 200/40 mg daily) or the escalation group (ES; starting at 40/8 mg and increasing incrementally to 200/40 mg daily) and treated for 24 weeks, then observed for 52 weeks. The primary endpoint, the PCP non-incidence rate (non-IR) at week 24, has been reported previously. The secondary endpoints were the PCP non-IR at week 52, treatment discontinuation rate and adverse events. Fifty-eight, 59 and 55 patients in the SS, HS and ES, respectively, received SMX/TMP. PCP did not develop in any of the patients by week 52. The estimated PCP non-IR in patients receiving SMX/TMP 200/40 mg daily (HS and ES) was 96.8-100%. Throughout the 52-week observation period, the overall discontinuation rate was significantly lower in HS than in SS (22.7 SMX/TMP 200/40 mg had a high PCP prevention rate and was superior to SMX/TMP 400/80 mg in terms of drug retention and safety. University Hospital Medical Information Network Clinical Trials Registry, UMIN000007727.
Identifiants
pubmed: 33134810
doi: 10.1093/rap/rkaa029
pii: rkaa029
pmc: PMC7585401
doi:
Types de publication
Journal Article
Langues
eng
Pagination
rkaa029Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
J Antimicrob Chemother. 2016 Sep;71(9):2397-404
pubmed: 27550992
Ann Rheum Dis. 2018 May;77(5):644-649
pubmed: 29092853
Arch Intern Med. 1996 Jan 22;156(2):177-88
pubmed: 8546551
Ann Intern Med. 1984 May;100(5):663-71
pubmed: 6231873
J Natl Compr Canc Netw. 2016 Jul;14(7):882-913
pubmed: 27407129
Arch Intern Med. 1995 Jun 12;155(11):1125-8
pubmed: 7763117
JAMA. 1983 Apr 1;249(13):1743-5
pubmed: 6827763
Intern Med J. 2014 Dec;44(12b):1350-63
pubmed: 25482745
Arthritis Res Ther. 2017 Jan 18;19(1):7
pubmed: 28100282
Arthritis Res Ther. 2014 Feb 05;16(1):R43
pubmed: 24495443
Mayo Clin Proc. 1996 Jan;71(1):5-13
pubmed: 8538233
Mod Rheumatol. 2016 Jul;26(4):557-61
pubmed: 26587755
N Engl J Med. 2007 Nov 1;357(18):1874-6
pubmed: 17978303
Cochrane Database Syst Rev. 2014 Oct 01;(10):CD005590
pubmed: 25269391
Mod Rheumatol. 2013 Jul;23(4):752-8
pubmed: 22907597
Med Mal Infect. 2014 May;44(5):185-98
pubmed: 24630595
BMC Infect Dis. 2019 Apr 5;19(1):311
pubmed: 30953458
Am J Transplant. 2013 Mar;13 Suppl 4:272-9
pubmed: 23465020
N Engl J Med. 2004 Jun 10;350(24):2487-98
pubmed: 15190141